Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Nov 29
Show Filter
08:30 - 08:50

Morning Coffee and Networking

More
Showing of Streams
10:30 - 11:20

Morning Break

More
Showing of Streams
13:30 - 14:50
Info
Showing of Streams
16:30 - 16:35
End of Conference Day Three

End of Conference Day Three

More
08:30 - 08:50 20 mins
Morning Coffee and Networking
08:50 - 09:00 10 mins
STREAM 7: Patient Recruitment & Retention
Opening remarks from the Chairperson
  • Andrew Benson - Senior Director at Trialtrove, Citeline
08:50 - 09:00 10 mins
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
Opening remarks from the Chairperson
  • Anna Matranga - Strategic Sourcing R&D, Consultant, AMC Alliances and Consulting
08:50 - 09:00 10 mins
STREAM 9: Regulatory Updates
Opening remarks from the Chairperson
  • Julianne Hull - CEO, WenStar Enterprizes
08:50 - 09:00 10 mins
STREAM 10: Artificial Intelligence in Clinical Trials
Opening remarks from the Chairperson
08:50 - 09:00 10 mins
EARLY CLINICAL DEVELOPMENT
Chairperson's Opening Remarks
09:00 - 09:30 30 mins
Info
STREAM 7: Patient Recruitment & Retention
CASE STUDY: Informing and empowering patients by providing access to their data and new research opportunities.
  • Caroline Feys - Clinical Innovation Leader, Janssen, Belgium

Research indicates that patients want access to their data, also while they are participating in a clinical trial. But why would patients really need access to their health data, after all, aren’t their investigators the ones who truly need to be in the know? Under older healthcare models that may have been true, but the healthcare industry transitions into patient-centred care models and patients want to be empowered with their own health data. Janssen Clinical Innovations (JCI) has developed the Janssen Global Trial Community in which we want to empower patient by providing access to their data, study information, feedback moments and new research opportunities to foster engagement and to create a long-term partnership build on transparency, trust and awareness.

09:00 - 09:30 30 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
CASE STUDY: Patient Reported Outcomes and beyond: A Self-Service setup
  • Angelo Trotta - Connected Health Solutions & Operations, Janssen, Pharmaceutical Companies of Johnson & Johnson, Belgium
  • How we currently deploy ePRO and mobile apps within clinical trials
  • Challenges we’re facing with ePRO and mobile apps
  • Self-Service model for ePRO and beyond: pilot setup
  • How can we effectively scale up
  • Unified support model
09:00 - 09:30 30 mins
Info
STREAM 9: Regulatory Updates
Clinical trial regulations in Canada
  • Dr. Carole Légaré MD - Director, Office of Clinical Trials, Health Products and Food Branch, Health Canada
  1. Overview of the Canadian regulatory framework for clinical trials
  2. Why you should consider bringing your trial to Canada
09:00 - 09:30 30 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
A Survey of Machine Learning Applications in Clinical Trials
  • Faisal Khan - Executive Director, AstraZeneca, USA
  • Operational: Running clinical trials better, faster and more efficiently
    • Site Selection
    • Patient Recruitment and Enrolment Modelling
    • Investigator Performance Analytics
    • Supply Chain Analytics
  • Scientific:

    • Integrating wearables
    • Removing manual steps (Cardiovascular event adjudication)
    • Integrating companion diagnostics
    • Integrating Medical Image screening
09:00 - 09:30 30 mins
Info
EARLY CLINICAL DEVELOPMENT
Putting the patient first: Practically applying a patient centric approach to early phase study design
  • Wolfgang Eglmeier - Head Centre for Clinical Trials Witten/Herdecke University (ZKS-UW/H), Witten/Herdecke University, Faculty of Health
  • Implementing patient centricity from PoC to ensure drug doesn’t fail in later stages
  • The benefits of early involvement of patient support groups to guide development
  • Use of social media to foster patient centricity
  • Best ways for detection of possible benefit of the drug: Stratification, biomarkers, endpoints, PROs
09:30 - 10:00 30 mins
Info
STREAM 7: Patient Recruitment & Retention
Patient engagement - what is it and how do we make sure we are doing it right?"
  • Russell Wheeler - Trustee, Leber's Hereditary Optic Neuropathy Society (LHON Society), UK
  • Patient engagement - defining the undefinable
  • Best practice in implementation of patient engagement
  • Early evidence and reasons to be optimistic
09:30 - 10:00 30 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
The role of Patient Reported Outcomes (PROs) and Quality of Life Measures in trials and clinical practice
  • Galina Velikova - Professor of Psycho-social and Medical Oncology, University of Leeds, UK
  • Monitoring of patients’ physical and psychological problems during and after cancer treatment is essential in modern oncology practice.  Traditional clinical methods can be supplemented by Patient-Reported Outcome (PROs) measures. The potential role of PROs is recognized and endorsed by national and international practice guidelines.
  • This presentation will first provide a brief historical overview and define the terms used in the field, such as health status, health-related quality of life, patient-reported outcomes, clinical outcomes.
  • The second part will give examples of cancer clinical trials where QOL data provided important extra information for patients and oncologists.
  • The third part will focus on using PROs in clinical practice to monitor symptoms and side-effects during cancer treatment. There is increasing research evidence that using PROs in individual patient care in oncology is beneficial to patients, supporting communication, achieving better symptom control, and possibly better survival. A brief overview of this evidence will be provided, followed by an example of our experience in Leeds, UK of online monitoring of toxicity during cancer chemotherapy using patient self-reported side-effects integrated with the electronic patient records (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice- eRAPID research program funded by the National Institute for Health Research). The values and challenges of PROs integration in routine oncology practice will be discussed.
09:30 - 10:00 30 mins
Info
STREAM 9: Regulatory Updates
Strategies in preparation of the Clinical Trial Regulation
  • Amer Alghabban - Vice President GxP Quality Assurance, Compliance Training, Karyopharm Therapeutics Inc., Switzerland
  • The impact of the CTR on industry
  • Preparation required by industry to be ready for implementation in 2019
  • Changes needed to clinical trial studies and strategies to implement these requirements
09:30 - 10:00 30 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
Identifying the right mix of RPA & human oversight
  • What level of automation of RPA is right?
  • What will lead the best ROI for both large pharma and smaller biotech
  • What is the optimal path for implementing automation in house?
09:30 - 10:00 30 mins
Info
EARLY CLINICAL DEVELOPMENT
Facilitating collaboration between industry and academia in the discovery and development of new medicines: A Cancer Research UK Perspective
  • Nigel Blackburn - Director of Drug Development, Cancer Research, UK
  • Drug Discovery and Development at Cancer Research UK
  • CRUK Centre for Drug Development infrastructure and capabilities
  • fostering innovation through industry-academic partnership
  • our partnering models
10:00 - 10:30 30 mins
Info
STREAM 7: Patient Recruitment & Retention
Sponsored Speaking - Bracket
  • Jeff Lee - President eCOA and Patient Engagement, Bracket
10:00 - 10:30 30 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
What can Big Data tell us about recent trends in Real World Study Design and post-marketing commitments in the EU and US?
  • Dr. Alexandre Malouvier - Scientific Affairs Director, Real World Solutions, PRA Health Sciences, France
  • Compare and contrast EU versus US post-market commitments for marketed products overall and by therapeutic area
  • Examine trends over time in the types of study designs employed for marketed products, and whether studies were mandated versus voluntary
  • Profile the research burden associated with 1st in class products versus entrants into established classes
  • Determine if mandated post-market safety commitments have changed over time for products with the same mechanism of action
10:00 - 10:30 30 mins
Info
STREAM 9: Regulatory Updates
What Does Brexit Mitigation Look Like in Practice?
  • Pete Young - Director, Quality Director, Catalent
10:00 - 10:30 30 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
Artificial Intelligence in Clinical Trials Automation
  • Vitthal Gouri - Director, Clinical Solutions, ArisGlobal, UK
  • What automation?
  • Approach to automation in clinical trials
  • Technology(AI) adoption for clinical trials automation
  • Automation planning and implementation
  • Regulatory prospective of automation in clinical trials
  • Conclusion
10:00 - 10:30 30 mins
EARLY CLINICAL DEVELOPMENT
Increasing the value of your asset: Considerations for Phase I hybrid trials
  • Dr. Amitava Ganguli - Medical Director, Medical & Scientific Affairs, Clinical Pharmacology Services, Covance
10:30 - 11:20 50 mins
Morning Break
11:20 - 11:50 30 mins
STREAM 7: Patient Recruitment & Retention
Talk to fill
11:20 - 11:35 15 mins
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
CASE STUDY: Paediatrics Trials – what are their experiences?
  • Joana Claverol - Clinical Research Unit Manager, Barcelona Children’s Hospital Sant Joan de Déu, Spain
11:20 - 11:50 30 mins
Info
STREAM 9: Regulatory Updates
CASE STUDY: Sponsors responsibility for vendor oversight – impact from ICH E6R2 Guideline
  • Geoff Taylor - Director, Clinical Quality Assurance,, Eisai Product Creation Systems, UK
  • Need for new processes for vendor selection and oversight, including delegated activities.  
  • Who has overall responsibility, who needs to be involved and how does this work from a QA perspective?
  • Introducing risk management into vendor oversight, what is the best mechanism for doing this?
  • What might regulators expect under ICH GCP R2?
  • How to effectively implement and document vendor oversight
11:20 - 11:50 30 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
Case study: Development of a new digital gamification platform for children
  • Amir Lahav - Digital Innovation Lead, Pfizer, USA
  • Case study on providing child-friendly incentives to increase engagement and protocol adherence
11:20 - 11:50 30 mins
Info
EARLY CLINICAL DEVELOPMENT
CASE STUDY: NIMA – Advancing Science and Drug Development through Public – Private Collaborations
  • Anja Hijzen - Associate Director Clinical Scientist, Janssen, Pharmaceutical Companies of Johnson & Johnson, Belgium
  • Joined forces in a Consortium:
    • From Preclinical to Clinical
    • Clinical focus on Phase 1b/2 studies
  • A win-win situation: focus on advancing science and leveraging into clinical development strategies
  • What are the operational challenges and opportunities
11:35 - 11:50 15 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
Engagement of young people across Europe to improve paediatric clinical trials
  • Begonya Nafria Escalera - Patient Advocacy Manager in Research, Hospital Sant Joan de Déu, Spain
  • Paediatric clinical trials landscape for the upcoming years
  • Young advocates can have a voice and involvement along the lifecycle of medicines
  • Standardization of the young advocates participation in clinical trials needs to be a gold standard
  • Good practices about the involvement of young people along the lifecycle of medicines
11:50 - 12:20 30 mins
Info
STREAM 7: Patient Recruitment & Retention
CASE STUDY: Using primary care electronic medical records to identify study subjects in clinical trials of biomarkers
  • Frank Sullivan - Director of Research, University of St Andrews, UK
  • Recruitment to trials often fails
  • Studies within a trial (SWATs) are needed – but difficult
  • EMRs enable more Precision recruitment- e.g. 12K patients recruited to ECLS
  • Feasibility platforms e.g. SHARE and Patient Reported data (Tablet study)
  • Use tools to see what sites are applicable
  • Using epidemiological data- computer science and stats to optimise inclusion/exclusion criteria
11:50 - 12:20 30 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
Informed participation and patient empowerment: A patient-centred approach to give voice to the young patients and favour the paediatric research
  • Mariangela Lupo - Networking Manager, TEDDY - European Network of Excellence for Paediatric Clinical Research, Italy
  • Patient Empowerment and Patient Advocacy to draw on patient own knowledge and experience
  • Rarely these attempts to increase awareness for the patient involvement in clinical research pay attention to the paediatric population needs
  • The regulatory framework at European level to promote the children's active participation in the decision-making process and to increase awareness for the patient involvement  in vlinival research: EU Clinical Trials Regulation, Summaries of Clinical Trial Results for Laypersons; Ethical Considerations for Clinical Trials on Medicinal products conducted with Minors
  • The Challenges to be faced for the engagement of children requiring appropriate means and language
  • The need of a patients age-tailored approach to design Informed consent in paediatrics: the experience of TEDDY
  • Specifically tailored methods should be applied to the training and empowerment process of paediatric patients
  • The role for paediatric patients and the relevance of clinical and translational research (including patients' engagement in clinical trials, the consent issue, the patient -  reported outcomes in the context of paediatric rare diseases)
  • The role of Young Persons Advisory Groups (YPAGs) to overcome this gap: the Italian and Albanian experience
11:50 - 12:20 30 mins
Info
STREAM 9: Regulatory Updates
Emerging Markets in Global Clinical Trials
  • Nancy Meyerson-Hess - Associate Partner, admedicum Business for Patients GmbH & Co KG, Germany
  • Adama Ibrahim - Associate Director, Clinical Operations, Biogen, UK
  • Michael Makanga - Executive Director., European & Developing Countries Clinical Trials Partnership (EDCTP)
  • We will address the following aspects:
  • Why is is important to include emerging markets and diversity in global clinical development and clinical trials?
  • What needs to be considered in order to be successful: for the sponsor, the sites, the patients?
  • What are the regulatory drivers?
11:50 - 12:20 30 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
Intelligent digital advertising tactics for accelerating clinical trial recruitment
  • Case study on the use of digital advertising platforms in patient recruitment
  • Targeting candidates based on key inclusion/exclusion criteria
  • How this could offer the opportunity to reach previously untapped pools of participants
11:50 - 12:20 30 mins
Info
EARLY CLINICAL DEVELOPMENT
Challenges in early phase patient recruitment and ensuring representative populations
  • Javier Garcia-Corbacho - Head of Clinical Trials Unit of Clinic Institute of Haematological and Oncological Diseases (ICMHO), Early Phase Clinical Trials, Hospital Clinic, Spain
  • Understanding how to ensure the most realistic population possible
  • Defining the right endpoints for more efficient population samples
  • Selecting patient populations to prevent side effects from only showing in later phases
  • Practical advice on streamlining recruitment processes to reduce cost and time
12:20 - 13:00 40 mins
Info
STREAM 7: Patient Recruitment & Retention
PANEL: What are the reasons and motivations for persons to participate in trials and how to achieve patient engagement?
  • Sammy Ainsworth - Patient Research Ambassador, committee member of Lupus UK, a board member of ENCA and Chair of the young person’s charity RAiISE, RAiISE, UK
  • Ben Cromarty - North Yorkshire AIDS Action (NYAA), UK Community Advisory Board (UK-CAB), Medical Research Council Clinical Trials Unit at University College London Patient and Public Involvement Group, UK
  • Svilen Konov - Director, SEVT Ltd, UK
  • Kate O’Brien - Senior Research Nurse, Freelance Site Consultant, UK
  • Richard Stephens - Chair of the National Cancer Research Institute's Consumer Forum, NCRI, UK
  • Increased involvement of patients in clinical trials for the trial design - How do we innovate clinical trials to include input from patients?
  • How to reach patient groups? Different aspects?
  • Improve the trial design – e.g. provide childcare for trial participants, compensation, travel costs, global differences, should patients receive financial compensation? A controversial area
  • Patient receives good clinical care already, why would they want to undertake a new medication trial? Why enter a clinical trial with a new substance if already have a good standard of care- how to attract? What would be the motivation?
  • How to make trials more attractive to patients?
  • Flexibility have home care visits- nurses to send to home
  • Better understanding of the gap between what patients expect and what drs are delivering when it comes into information of clinical trials
  • What can patients contribute to the trial design / development of trial protocols?
  • How can they be actively involved in all levels of the trial (including steering committees etc)
12:20 - 13:00 40 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
PANEL: Now, next and future for clinical trial design?
  • Roland Rich - Operations Expert, DevQA, Novartis, France
  • Dmitry Manuilov - Head of Clinical Development, MYR GmbH, Germany
  • Margi Sheth - Clinical Information sharing Programme Manager, AstraZeneca
  • Ursula Garczarek - Associate Director of Strategic Consulting, Cytel
  • Matt Cooper - Business Development & Marketing Director, NIHR
  • How virtual can we go?
  • Looking at all the different trial options- advantages and disadvantages
  • Why we do it and the benefits of platform studies?
12:20 - 13:00 40 mins
STREAM 9: Regulatory Updates
Spotlight session from Deloitte
12:20 - 13:00 40 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
PANEL DISCUSSION: Achieving improved patient centricity and engagement with the use of AI – Opportunities and Limitations
  • Faisal Khan - Executive Director, AstraZeneca, USA
  • Mishal Patel - Global Head of Heath Informatics, AstraZeneca
  • Kevin Hua - Senior Manager AI/Machine Learning Development, Bayer Life Sciences iHub, USA
  • Is there an opportunity to effectively and efficiently use ambient listening devices?
  • How can AI and machine learning be leveraged
  • Detection of adverse events?
  • The use of NLP and other strategies for analysis?
12:20 - 13:00 40 mins
Info
EARLY CLINICAL DEVELOPMENT
PANEL DISCUSSION: Outsourcing early clinical trials
  • Nigel Blackburn - Director of Drug Development, Cancer Research, UK
  • Anja Hijzen - Associate Director Clinical Scientist, Janssen, Pharmaceutical Companies of Johnson & Johnson, Belgium
  • Jaclyn Patterson - Senior Director, Early Dev. Clinical Trial Management, Regeneron, USA
  • Shaila Shabbir - Clinical Development Manager, Respiratory Global Clinical Sciences & Delivery (GCSD), R&D Projects, GlaxoSmithKline
  • Experiences and challenges with outsourcing to CROs in the early phase
  • What are we looking for in an early phase CRO?
  • Should sponsors adopt a different approach to using/managing CRO’s in early phase vs late phase?
  • CROs vs. academic institutions
  • Studies in patients vs studies in healthy volunteers
13:00 - 13:30 30 mins
STREAM 7: Patient Recruitment & Retention
Sponsored Speaking Slot to Fill
13:00 - 13:30 30 mins
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
Real World Data: Improving clinical trial design and patient recruitment
  • Michelle Jones - Senior Director, Clinical Informatics, and Feasibility, Recruitment & Engagement (FRE), Covance
13:00 - 13:30 30 mins
Info
STREAM 9: Regulatory Updates
The Clinical Trials Regulation in the context of Paediatric Research
  • Dr. Martine Dehlinger-Kremer - Vice President, Pediatric Development, Synteract
13:00 - 13:30 30 mins
STREAM 10: Artificial Intelligence in Clinical Trials
Innovation Den
13:00 - 13:30 30 mins
Info
EARLY CLINICAL DEVELOPMENT
Preclinical development, Research Infrastructures and CRO partnership.
  • Giovanni Migliaccio - Scientific Director, Consorzio per Valutazioni Biologiche e Farmacologiche
  • Increased involvement of academic institution in translational medicine, opportunities and challenges.
  • Success rate in late clinical development, how to improve it?
  • CRO and preclinical development, how to get involved?
  • European research infrastructures. EPTRI, a new kid on the block in the preclinical and clinical development.
  • Cost-Benefit and the non-profit approach to drug development
13:30 - 14:50 80 mins
Info
Lunch
14:50 - 15:00 10 mins
EARLY CLINICAL DEVELOPMENT
Opening remarks form Chairperson
  • Julianne Hull - CEO, WenStar Enterprizes
15:00 - 16:00 60 mins
STREAM 7: Patient Recruitment & Retention
Please go to stream 8, 9 or 10
15:00 - 15:30 30 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
CASE STUDY: Collaborative studies and platform studies – changing the scope of clinical research
  • Katrin Haeverans - Clinical Scientist and External Affairs Director, Janssen (EMEA), Belgium
  • The sad truth about Alzheimer’s Dementia
  • EPAD (Early Prevention of Alzheimer’s Disease)– A New Era for Performing Prevention studies using a platform approach
  • EPAD Consortium joining forces - Framework and Scene setting
  • Building a Platform
  • What are the operational challenges?
  • What is the added value for pharma companies?
15:00 - 15:30 30 mins
Info
STREAM 9: Regulatory Updates
CASE STUDY: Inspectors experience’s on GDPR and ICH E6R2
  • A Representative from Merck, Merck, UK
  • A sponsor/inspector case study of how they have built a risk management plan
  • How implement a risk management plan including best practices for communication with CRO
  • Inspector feedback on experiences of GDPR checks
  • Valuable insight on how industry is expected to handle patient and trial data
15:00 - 15:20 20 mins
EARLY CLINICAL DEVELOPMENT
Early phase study design for gene therapies
  • Vijay Zala - Clinical Project Manager, Imperial College London, UK
15:20 - 15:40 20 mins
Info
EARLY CLINICAL DEVELOPMENT
Early clinical development in neuromuscular rare disease
  • Wojciech Smoron - Assoc. Global Trial Director, Novartis
  • Challenges and opportunities
  • Development strategy
  • Exceptional, not conventional approach
15:30 - 16:00 30 mins
Info
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
Big Health Data –Insights you can generate from routine data sources... if you still "haven’t found what you are looking for"
  • Daniel Prieto- Alhambra - Associate Professor & NIHR Clinician Scientist, Oxford University, UK
  • Start here: Data discovery, what is out there? Their Pros and Cons
  • First steps: big health data to inform patient recruitment
  • Letting go for a while: Routine data linkage for long-term follow-up in trials
  • The aftermath: Big healthcare data for post-marketing drug and device surveillance
15:30 - 16:00 30 mins
Info
STREAM 9: Regulatory Updates
The impact on patient data under GDPR
  • Kristof Van Quathem - Special Counsel, Covington & Burling LLP, Belgium
  • How we protect patient data?
  • Strategies to get GDPR compliance
  • Understanding the requirements of collected images such as chest X-Rays. Do we need to remove their name?
  • What does it mean for clinical research consent? Will people able to consent to certain parts of the trial?
15:30 - 16:00 30 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
Making all data machine learnable
  • Mishal Patel - Global Head of Heath Informatics, AstraZeneca
  • Leveraging data for machine learning projects
  • Implementing robust data standards
  • Analysing big data using machine learning algorithms
15:40 - 16:00 20 mins
Info
EARLY CLINICAL DEVELOPMENT
Applying seamless early phase study design concepts from oncology
  • Riccardo Belli - Director, Novartis Oncology
  • Applying seamless trial design for early clinical development from clinical studies focused on oncology treatments
  • An outline of how seamless studies could reduce costs and timescales of early development
  • Discussing how and when seamless study designs can be applied to early phases trials for diseases other than oncology
  • Exploring the current regulatory view on seamless studies
16:00 - 16:30 30 mins
STREAM 8: Real World Evidence, Paediatrics, Trial Design & Big Data
Technology enablement and wealth of data
  • Roland Rich - Operations Expert, DevQA, Novartis, France
16:00 - 16:30 30 mins
Info
STREAM 9: Regulatory Updates
Panel discussions: Interaction with Industry and Member states on the landscape of regulatory compliance
  • Dr. med Uwe Gudat - Head of Clinical Safety & Pharmacovigilance, Fresenius Kabi SwissBioSim GmbH, Switzerland
  • Kristof Van Quathem - Special Counsel, Covington & Burling LLP, Belgium
  • The impact of Brexit on the regulatory landscape
  • The long-term effect of the GDPR and ICH
  • Preparations needed for the CTR
16:00 - 16:30 30 mins
Info
STREAM 10: Artificial Intelligence in Clinical Trials
Using AI to generate and test novel hypotheses – increasing efficient and accuracy of clinical trial processes
  • Kevin Hua - Senior Manager AI/Machine Learning Development, Bayer Life Sciences iHub, USA
  • How machine learning can be used to analyse complex data sets
  • The use of programs to generate and test novel hypotheses more efficiently than traditional processes – thus enabling much faster and more accurate clinical trial periods
16:00 - 16:20 20 mins
EARLY CLINICAL DEVELOPMENT
Early Clinical Trial in Oncology and Rare Disease
  • Gianluca Laus - Indication Lead Director role, AstraZeneca
16:30 - 16:35 5 mins
End of Conference Day Three